SYDNEY -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has published an in-depth whitepaper titled “Vaccines - Global Clinical Trial Landscape (2024).” This report provides a comprehensive analysis of the evolving vaccine development landscape, offering strategic insights for biotech and pharma stakeholders.

The whitepaper examines trends in prophylactic and therapeutic vaccine trials, highlighting advancements and emerging challenges. Key topics covered include the expansion of mRNA platforms, innovative delivery methods, and efforts toward equitable vaccine access by organizations such as WHO and Gavi.

Highlights:

· Emerging Trends: A shift towards adaptive trial designs, personalized vaccine trials, and novel delivery methods addressing infectious diseases and cancer.
· Regional Analysis: Clinical trial activity by region, emphasizing Asia-Pacific’s increasing role in vaccine development, especially in therapeutic vaccines.
· Investment Landscape: A summary of venture funding and M&A activity, with a focus on infectious and oncology vaccines.
· Regulatory Developments: Insights into streamlined regulatory processes established after COVID-19, aiming to expedite vaccine approvals and enhance pandemic preparedness.

The whitepaper is available for download, providing actionable data and strategic guidance on navigating regulatory complexities, patient recruitment, and leveraging new vaccine technologies.